Press
PinCell’s studies open up new indications for lead candidate
Two pre-clinical studies carried out by leading dermatologist Dr. Riichiro Abe, Professor and Chair of Dermatology at Niigata University, indicate that PC111 monoclonal antibody can ease Stevens-Johnson Syndrome by eliminating excess of circulating Fas ligand.Severe...
PinCell announces 2 successful in-vivo studies for breakthrough skin disease therapy
Proprietary transgenic mouse produces human form of FasL protein May 4, 2023 - MILAN - PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent...
PinCell announces the development of a key transgenic mouse model and the appointment of Dr. Antonino Amato as CEO
The biotechnology company has established a promising in-vivo platform for the development of its lead therapy, a monoclonal antibody that stops blistering in chronic skin conditions without suppressing the immune system. January 19, 2023 - MILAN - PinCell, a...
PinCell appoints veteran biotech and biopharma executives to Management Team and Board of Directors
The nominations follow a successful seed funding led by Sofinnova Partners MILAN, Italy - May 6, 2020 - PinCell, a biotechnology company developing novel therapies for rare dermatological diseases, announced today the appointment of Gabriella Camboni, M.D., as Chief...
Malattie rare, scoperta made in Modena
Il prof. Pincelli e la dottoressa Marconi hanno creato un farmaco contro il pemfigo che non deprime il sistema immunitario di Davide Berti - Gazzetta di Modena - 22.06.2015 - Ricerca, speranza e nuova cura. Sono queste le parole d’ordine. Due medici modenesi, il...
Pincell sul podio di Innova Day
Nell’ambito dell’iniziativa organizzata da Democenter e ateneo gli investitori hanno premiato una start-up dell’Università di Modena e Reggio Emilia - 12.01.2010 - Tra le tre imprese premiate dagli investitori all'interno di Innova Day, l'evento organizzato da...